Genetic discrimination occurs when people are treated differently by their employer or insurance company because they have a gene mutation that causes or increases the risk of an inherited disorder. Fear of discrimination is a common concern among people considering genetic testing.
Several laws at the federal and state levels help protect people against genetic discrimination. In particular, a federal law called the Genetic Information Nondiscrimination Act (GINA) is designed to protect people from this form of discrimination. However, GINA does not apply to life insurance because it is regulated by the states.
Lack of protection against genetic discrimination in obtaining life insurance has caused many individuals to defer and not undergo genetic testing. In addition, for those who receive results from genetic testing through direct-to-consumer methods, they may shy away from sharing reports with their physicians because the results could be document in their medical records. Life insurers, on the other hand, fear that consumers will obtain more coverage than what they would ordinarily obtain, although no evidence supports this conclusion. In the United States, only the state of Florida has banned life insurance companies from using genetic information, defined as the results of predictive genetic tests, in underwriting unless the information is accompanied by a diagnosis of a medical condition. This means that carriers of autosomal recessive or X-linked disorders are protected. Several other countries, including Australia, Canada, and South Korea, already restrict the use of predictive genetic test results by life insurers.
Because of the individual state regulation of life insurance in the US, it will require an initiative from insurers to self-regulate their practices regarding genetic discrimination. If self-regulation does not mitigate discrimination, then the life insurers will need to collaborate with the other stakeholders and government to adopt a policy that adequately balances the competing economic and social arguments on both sides of the aisle.
Genetic counselors are uniquely positioned as stakeholders to shape policies. Their daily professional demands require them to stay abreast of rapidly evolving information in genetics. Laws, on the other hand, are glacially slow to change. Genetic counselors should be aware of the current and pending legislation in the states where they practice. They should also be seated at the table to help state insurance commissioners and simultaneously advocate for patients. All parties need the same information to ensure that genetic information is not misused.
Banning Genetic Discrimination in Life Insurance — Time to Follow Florida’s Lead
The Florida Senate: HB 1189 — Genetic Information for Insurance Purposes
Please log in to ObGFirst to access the 2T US Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
